Watch hVIVO’s July 2024 Capital Markets Day here
Yamin 'Mo' Khan
CEO at hVIVO
“After an exceptionally strong first half with record revenues and margins, hVIVO enters the remainder of the year with FY24 revenue guidance fully contracted and good visibility into 2025. We continue to expand our pipeline, not only in human challenge trials but also in our new revenue streams including clinical site studies, standalone laboratory services, and participant / patient recruitment. Operational efficiencies are set to continue to improve with the expansion of our services, improved automation, and the move to our new facility in Canary Wharf."
A rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, providing end-to-end early clinical development services for our broad and longstanding global client base of biopharma companies.
Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.
hLAB is a highly specialised virology and immunology laboratory offering a suite of services to support pre-clinical and clinical respiratory drug and vaccine discovery & development.
FluCamp welcomes participants to take part in our clinical trials under expertly supervised conditions.
